Peptide Bivalirudin...

Peptide Bivalirudin Trifluoroacetate
Peptide Bivalirudin Trifluoroacetate
Peptide Bivalirudin Trifluoroacetate
Peptide Bivalirudin Trifluoroacetate
Peptide Bivalirudin Trifluoroacetate

Peptide Bivalirudin Trifluoroacetate

Min.Order / FOB Price:Get Latest Price

50 Milligram

FOB Price: USD 6.0000

  • Min.Order :50 Milligram
  • Purity: 98.8%
  • Payment Terms : L/C,D/A,D/P,T/T,

Keywords

Bivalirudin Trifluoroacetate Bivalirudin Trifluoroacetate

Quick Details

  • Appearance:White Crystal Powder
  • Application:Bivalirudin is a synthetic new anticoagulant, thrombin direct, specific, reversible inhibitor.
  • PackAge:According to Customer's Requirement
  • ProductionCapacity:10|Gram|Day
  • Storage:Keep Cold
  • Transportation:Shipment : TNT ,DHL ,HKEMS ,HKEUB ,FEDEX by Air .

Superiority:

Quality

Our company is a professional production of hormone intermediates for many years, our products have exported to Germany,Spain, UK, USA, Australia, Middle East, and so on other country, and we have got very good feedback from our customers, you can trust us.And we are the manufactory, so no problem for us to control the quality.

Payment Method

Western Union,TT,Money Gram 

Service 

Best service with after-sales service to all clients.

Delivery

Sample Order :Package will be shipped with 3days after payment. We can send it via UP, EMS, HK Air Post, DHL or othermethod. We have a professional and stable logistics, and we can deliver the package smoothly around 3 to 5 days.

 

Details:

Peptide Bivalirudin Trifluoroacetate 

Molecular Formula:

C98H138N24O33

Relative Molecular Mass:

2180.32 g/mol

CAS-Number:

128270-60-0 (net)

Long-term Storage:

-20 ± 5 °C

Synonyms:

BG 8967; Hirulog; Hirulog I

Sequence:

H-D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH trifluoroacetate salt

 

Fields of Application:

Moderate to high risk acute coronary syndromes

Percutaneous coronary intervention

 

Active Substance:

Bivalirudin is a synthetic hirudin analog. Bivalirudin acts as a specific and reversible direct thrombin inhibitor.

------Product Description------

Bivalirudin is a new synthetic anticoagulant, thrombin direct, specific, reversible inhibitor. Initially developed by the Swiss company of Biogen (Biogen) successfully transferred to the United States after the MedicinesCompany, approved in 2000 in the United States. Its anticoagulant component is a hirudin-derived 20-peptide compound. Whether thrombin in the blood circulation, or thrombin-bound thrombin, bivalirudin can be combined with its catalytic site and anionic binding sites of specific binding, thereby inhibiting the activity of thrombin directly, and its role is characterized by a brief ,reversible. Early clinical studies have shown that anticoagulant therapy with bivalirudin is more effective and has a lower incidence of bleeding events and is safer than conventional heparin anticoagulation. Mainly for the prevention of angioplasty interventional treatment of unstable angina before and after ischemic complications.

In vitro this product on the soluble and thrombus-bound thrombin inhibition, the role of platelet release from the product, and in a dose-dependent manner to extend the activation of normal plasma partial thromboplastin time, coagulation Enzyme time and prothrombin time. For percutaneous coronary intervention (PCI) of unstable angina. 2010, the number of domestic PCI surgery to 300,000 cases, the annual compound growth rate of more than 30%, showing that after the sale of bivalirudin after the listing of promising.
Clinical trials have shown that bivalirudin is superior to the current combination of unfractionated heparin / low molecular weight heparin + platelet glycoprotein receptor antagonists in peripheral PCI applications, with a significantly reduced risk of bleeding, significantly increasing anticoagulant use safety:
(1) The incidence of bleeding can be significantly reduced in patients with elective PCI and the overall clinical outcome risk is reduced by 14%.
(2) does not cause antibody-mediated thrombocytopenia.
(3) and reversible thrombin binding, short half-life, not prone to ischemic and hemorrhagic complications.
(4) the main excretion does not pass the kidney, can be safely used in patients with renal damage.
As an alternative to unfractionated heparin and platelet glycoprotein IIb / IIIa antagonists

-----Company Info------ 

Filter Biotechnology Co., Ltd is a High-Tech Bio-Chemical Enterprise which is integrated by Professional Scientific R&D, Mass production and Sales. As a world-leading Provider of Peptide Reagents, Generic Peptides and Custom Peptide Synthesis Services., it has been faithfully serving the Biotech and Pharmaceutical Industries, as well as well as life science research institutes, Universities and Medical Cosmetology Organization worldwide. 

In accordance with Relevant Regulations in China, , xxx certified with GMP Certification, actively implemented international Quality Standards and established a perfect Quality Management System. 

With the linking Enterprise Quality Assurance Agences and conscientious Quality Standard Audit Systems, it could gurantee the Good Quality on the Production Process and the Finished goods. 

Insisting on Faith, Mutual Beneficial Cooperation and Professional, conscientious and efficient work practices and combining the Excellent Inner Techniques and External Resources, XXX fully respect on Clients requirements to actively offer Highly Standard, Specialiezed and Professional Services around the world .

-----Lab-----

-----Contact US -----

Krystal 

Phone :0086-15737953140

Facebook :calarhan1993@126.com

Skype :calarhan1993@126.com

 

Related Searches

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View